Cipla’s child friendly AIDS formulation gets US FDA approval
Cipla, a major pharmaceutical company has been approved by the US health regulator USFDA for manufacturing Lopinavir and Ritonavir oral pellets which can be used for treating infantile AIDS.
The USFDA has approved a new innovative formulation — Lopinavir/Ritonavir 40mg/ 10 mg oral pellets under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, said Cipla.
Cipla MD & Global CEO Subhanu Saxena said “This innovative way of drug delivery through oral pellets for some of society’s youngest AIDS sufferers reiterates our commitment to provide access to life saving medicines in the fight against HIV/ AIDS.”
The pellets can be mixed with porridge or other foods for children and administered. The pellets are produced by melt-extrusion technology and are enclosed in capsules, Cipla said.
As per (UNAIDS — The Gap Report 2014), globally 3.2 million children were living with HIV in 2013 and 240,000 children were newly infected with HIV, Cipla said.
The USFDA has approved a new innovative formulation — Lopinavir/Ritonavir 40mg/ 10 mg oral pellets under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, said Cipla.
Cipla MD & Global CEO Subhanu Saxena said “This innovative way of drug delivery through oral pellets for some of society’s youngest AIDS sufferers reiterates our commitment to provide access to life saving medicines in the fight against HIV/ AIDS.”
The pellets can be mixed with porridge or other foods for children and administered. The pellets are produced by melt-extrusion technology and are enclosed in capsules, Cipla said.
As per (UNAIDS — The Gap Report 2014), globally 3.2 million children were living with HIV in 2013 and 240,000 children were newly infected with HIV, Cipla said.
Next Story
